KRAS and cancer: BI 2865, a newly developed non-covalent, selective inhibitor targeting the inactive state of KRAS, shows broad preclinical efficacy against diverse KRAS mutants, supporting the potential of pan-KRAS inhibition as a therapeutic strategy in KRAS-driven cancers [167].